Lexeo Therapeutics Files S-1 for Potential IPO

Ticker: LXEO · Form: S-1 · Filed: Apr 9, 2024 · CIK: 1907108

Lexeo Therapeutics, Inc. S-1 Filing Summary
FieldDetail
CompanyLexeo Therapeutics, Inc. (LXEO)
Form TypeS-1
Filed DateApr 9, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $13.16
Sentimentneutral

Sentiment: neutral

Topics: Lexeo Therapeutics, S-1 Filing, IPO, Biotechnology, SEC Filing

TL;DR

<b>Lexeo Therapeutics, Inc. has filed an S-1 registration statement, signaling its intent to pursue an Initial Public Offering.</b>

AI Summary

Lexeo Therapeutics, Inc. (LXEO) filed a IPO Registration (S-1) with the SEC on April 9, 2024. Lexeo Therapeutics, Inc. filed an S-1 registration statement on April 9, 2024. The company is in the Biological Products (No Diagnostic Substances) industry. Fiscal year ends December 31st. The filing includes data for fiscal years ending December 31, 2022, and December 31, 2023. Key dates include October 13, 2023, and November 7, 2023, related to previous filings or events.

Why It Matters

For investors and stakeholders tracking Lexeo Therapeutics, Inc., this filing contains several important signals. This S-1 filing is a crucial step for Lexeo Therapeutics as it seeks to raise capital through a public offering, which could fund its research and development efforts in the biotechnology sector. The filing provides potential investors with detailed financial information and business strategies, allowing them to assess the company's viability and growth prospects before it becomes publicly traded.

Risk Assessment

Risk Level: medium — Lexeo Therapeutics, Inc. shows moderate risk based on this filing. The company is in the early stages of development, as indicated by the S-1 filing which typically precedes significant operational scaling and revenue generation. Specific financial performance data for the current fiscal year is not yet available in this initial filing.

Analyst Insight

Monitor Lexeo Therapeutics' S-1 filing for detailed financial projections, pipeline updates, and management commentary to assess its IPO readiness and long-term potential.

Key Numbers

  • 2024-04-09 — Filing Date (S-1 filing date)
  • 2022-12-31 — Fiscal Year End (Previous fiscal year end)
  • 2023-12-31 — Fiscal Year End (Most recent fiscal year end)
  • 2023-11-07 — Key Date (Significant date mentioned in filing)

Key Players & Entities

  • Lexeo Therapeutics, Inc. (company) — Filer name
  • 345 PARK AVENUE SOUTH (company) — Business address
  • NEW YORK (company) — Business address city
  • NY (company) — Business address state
  • 10010 (company) — Business address zip
  • 2836 (company) — Standard Industrial Classification code
  • 854012572 (company) — IRS number
  • 333-278566 (regulator) — SEC file number

FAQ

When did Lexeo Therapeutics, Inc. file this S-1?

Lexeo Therapeutics, Inc. filed this IPO Registration (S-1) with the SEC on April 9, 2024.

What is a S-1 filing?

A S-1 is a registration statement for initial public offerings, containing the prospectus with business description, financials, and risk factors. This particular S-1 was filed by Lexeo Therapeutics, Inc. (LXEO).

Where can I read the original S-1 filing from Lexeo Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Lexeo Therapeutics, Inc..

What are the key takeaways from Lexeo Therapeutics, Inc.'s S-1?

Lexeo Therapeutics, Inc. filed this S-1 on April 9, 2024. Key takeaways: Lexeo Therapeutics, Inc. filed an S-1 registration statement on April 9, 2024.. The company is in the Biological Products (No Diagnostic Substances) industry.. Fiscal year ends December 31st..

Is Lexeo Therapeutics, Inc. a risky investment based on this filing?

Based on this S-1, Lexeo Therapeutics, Inc. presents a moderate-risk profile. The company is in the early stages of development, as indicated by the S-1 filing which typically precedes significant operational scaling and revenue generation. Specific financial performance data for the current fiscal year is not yet available in this initial filing.

What should investors do after reading Lexeo Therapeutics, Inc.'s S-1?

Monitor Lexeo Therapeutics' S-1 filing for detailed financial projections, pipeline updates, and management commentary to assess its IPO readiness and long-term potential. The overall sentiment from this filing is neutral.

Key Dates

  • 2024-04-09: S-1 Filing — Indicates intent to go public and provides initial disclosure.
  • 2023-12-31: Fiscal Year End — Marks the end of the most recent full fiscal year for which data is presented.
  • 2022-12-31: Fiscal Year End — Marks the end of the prior fiscal year for comparative financial analysis.
  • 2023-11-07: Filing Date — A significant date related to previous company disclosures or events.

Filing Stats: 4,450 words · 18 min read · ~15 pages · Grade level 17.8 · Accepted 2024-04-09 08:01:59

Key Financial Figures

  • $0.0001 — he "Shares") of common stock, par value $0.0001 per share ("Common Stock"), of Lexeo Th
  • $13.16 — Common Stock as reported on Nasdaq was $13.16 per share. We are an "emerging growth

Filing Documents

Use of Proceeds

Use of Proceeds 84 Market Price of the Registrant's Common Equity and Related Stockholder Matters 85

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 86

Business

Business 98 Certain Relationships and Related Person Transactions 158 Management 165

Executive Compensation

Executive Compensation 172 Principal and Selling Securityholders 187

Description of Capital Stock

Description of Capital Stock 192 Securities Act Restrictions on Resale of Securities 198 Material U.S. Federal Income Tax Considerations For Non-U.S. Holders of Our Common Stock 199 Plan of Distribution 203 Legal Matters 206 Experts 206 Where You Can Find Additional Information 207 Index to Consolidated Financial Statements F-1 You should rely only on the information contained in this prospectus or in any applicable prospectus supplement prepared by us or on our behalf. Neither we nor the Selling Stockholders have authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the Selling Stockholders are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the Selling Stockholders hereunder may, from time to time, sell the shares offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Stockholders of the securities offered by them described in this prospectus. We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this pros

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.